• All Categories
  • UK News
  • Europe
  • Global
  • R & D
  • Sales & Marketing
  • Manufacturing
  • Digital
  • Industry Insights
  • Appointments
  • Interviews
  • Features
  • Industry Facts
Measles outbreak possible, advises UKHSA
Measles outbreak possible, advises UKHSA

The UKHSA has warned that further outbreaks of measles could spread to other towns and cities unless uptake in the measles, mumps and rubella vaccination is increased in at-risk areas.

7 February 2024UK News
FDA approves skin cancer AI detection device
FDA approves skin cancer AI detection device

DermaSensor has announced that the FDA has granted clearance for its real-time, non-invasive skin cancer evaluation system.

7 February 2024Digital
PharmaTimes
PharmaTimes

Www.pharmatimes.com/intcr

7 February 2024
SAMEDAN - ICT
SAMEDAN - ICT

International Clinical Trials

7 February 2024
Comment
Comment

Welcome to the January/February 2024 issue of Pharmafocus!

7 February 2024
Contents
Contents

Welcome to the January/February 2024 issue of Pharmafocus!

7 February 2024
BioNTech’s Rwanda vaccine manufacturing site achieves milestone
BioNTech’s Rwanda vaccine manufacturing site achieves milestone

BioNTech has announced that it has reached the next milestone in the establishment of its mRNA vaccine manufacturing capacities in Africa, with the introduction of the new site in Kigali, Rwanda.

7 February 2024Manufacturing
Digital healthcare platform launched by Eli Lilly
Digital healthcare platform launched by Eli Lilly

Eli Lilly has announced its new digital healthcare experience, LillyDirect, which will benefit patients in the US with obesity, migraine and diabetes. This is intended to offer resources around disease management, such as access to healthcare providers, tailored support and delivery of selected medications.

7 February 2024Digital
AstraZeneca pays C4X an $11m milestone payment
AstraZeneca pays C4X an $11m milestone payment

C4X Discovery Holdings has announced that it has received a milestone payment of $11m from AstraZeneca, which was triggered by the preclinical progress of C4XD’s NRF2 activator programme.

7 February 2024Sales & Marketing
Pharma Role
Pharma Role

Pharmarole.com

7 February 2024
FDA grants Fast Track Designation for Verastem’s combination NSCLC treatment
FDA grants Fast Track Designation for Verastem’s combination NSCLC treatment

Verastem Oncology has announced that the FDA has granted fast track designation for the company’s investigational raf/mek clamp, avutometinib, in combination with amgen’s kras g12c inhibitor, lumakras (sotorasib) for the treatment of patients with kras g12c-mutant metastatic non-small cell lung cancer.

7 February 2024R & D
GSK’s Jemperli plus Zejula combination performs well in trial as endometrial cancer treatment
GSK’s Jemperli plus Zejula combination performs well in trial as endometrial cancer treatment

GSK has announced positive results from a planned analysis of the second part of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial

7 February 2024R & D